Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Mounjaro: Also contains tirzepatide and shares the same mechanism of action as Zepbound. It is branded for the treatment of Type 2 diabetes but is essentially the same compound as Zepbound.

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity.

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...

Zepbound: Recently FDA-approved in November 2023, it offers another option for patients seeking medical support for weight loss. Both medications have demonstrated excellent results in clinical ...

Is that the best course of action? Let's find out ... which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter. Besides the fact that the ...